EVOLUS INC (EOLS)
US30052C1071 - Common Stock
Thursday's pre-market session: top gainers and losers
Get insights into the top gainers and losers of Thursday's pre-market session.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out with our coverage of all the latest and greatest news happening on Thursday!
Notable Wednesday Option Activity: F, EOLS, RCL
Evolus to Report First Quarter Financial Results on May 7, 2024
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023
EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Evolus (NASDAQ:EOLS) just reported results for the fourth quarter of 2023.Evolu...
Notable Thursday Option Activity: PLAY, OKTA, EOLS
Evolus Announces Results from European Head-to-Head Filler Trial
Noteworthy Wednesday Option Activity: RH, IMAX, EOLS
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for AbbVie shows improving technical performance.
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Novo Nordisk Stock Just Earned A 92 RS Rating; Gapped Up On Earnings
Novo Nordisk ADR sees its Relative Strength Rating move into the elite 90-plus level.
Evolus, Alvotech gain as Barclays raises to Ovrweight (NASDAQ:ALVO)
Barclays upgrades Evolus (EOLS) and Alvotech (ALVO), leading to a run-up in their share prices. Find out reasons behind the upgrade.
Evolus Set For Promising 2024: Analysts Maintain Positive Outlook On Botox Alternative Maker
Evolus beats Q4 revenue expectations, up 40% YoY at $61M. Full-year 2023 hits $202M, exceeding guidance. Analysts bullish on Evolus.
Evolus shares rise on upbeat 2024 revenue outlook (NASDAQ:EOLS)
Evolus (EOLS) reported strong Q4 revenue with a 40% YoY increase, leading to a 5.5% jump in after-hours trading.
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AbbVie sees maintaining Botox position in aesthetics: report (NYSE:ABBV)
Despite increasing competition, AbbVie reportedly expects Botox to maintain its leading market share position in the aesthetics market. Read more here.
